Supernus claims epilepsy patent win

08-02-2016

Supernus claims epilepsy patent win

Kuzma / Shutterstock.com

Supernus Pharmaceuticals has defeated Actavis in a patent infringement dispute centring on epilepsy drug Oxtellar XR (oxcarbazepine).


Supernus Pharmaceuticals, patent infringement, Abbreviated New Drug Application, FDA, Actavis, Allergan, Oxtellar XR (oxcarbazepine)

LSIPR